Date: 2011-11-18
Type of information: Development agreement
Compound: certain of Shire’s Attention Deficit Hyperactivity Disorder (ADHD) medicines
Company: Shire (UK) Shionogi (Japan)
Therapeutic area: Mental diseases - Psychiatric diseases
Type agreement: development
commercialisation
Action mechanism:
Disease: Attention deficit hyperactivity disorder (ADHD)
Details: Shire has entered into an agreement with Shionogi & Co to co-develop and co-commercialize certain of Shire’s Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan.
Financial terms: Shionogi will pay a one time fee and share costs with Shire in exchange for rights to jointly co-develop and co-commercialize the products upon approval for the Japanese market. Specific terms of the agreement are not being disclosed.
Latest news:
